Confronto

Cerebrolysin vs. Semax

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

96889-70-6

80714-61-0

Peso molecolare

nessun dato

813.92 g/mol

Emivita

nessun dato

0.3 h

Sequenza

nessun dato

Met-Glu-His-Phe-Pro-Gly-Pro

Meccanismo d'azione

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Semax

Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Cerebrolysin	Semax
Austria	Su prescrizione	—
CN	Su prescrizione	—
Germania	Non chiaro	Non approvato
RU	Su prescrizione	Su prescrizione
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Cerebrolysin and Semax?: Cerebrolysin is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Semax?: The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Semax in Germany and the United States?: Germania: Cerebrolysin — Non chiaro, Semax — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Semax

Austria

Su prescrizione

—

Su prescrizione

—

Germania

Non chiaro

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Cerebrolysin and Semax?

Cerebrolysin is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Semax?

The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Semax in Germany and the United States?

Germania: Cerebrolysin — Non chiaro, Semax — Non approvato. Stati Uniti: Cerebrolysin — Non approvato, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.